Milestone Pharmaceuticals Inc. (MIST)

NASDAQ: MIST · IEX Real-Time Price · USD
1.790
-0.010 (-0.56%)
At close: Mar 28, 2024, 4:00 PM
1.752
-0.038 (-2.12%)
After-hours: Mar 28, 2024, 6:14 PM EDT

Company Description

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines.

The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.

It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers.

The company was incorporated in 2003 and is headquartered in Montréal, Canada.

Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals logo
Country Canada
Founded 2003
Industry Biotechnology
Sector Healthcare
Employees 47
CEO Joseph G. Oliveto M.B.A.

Contact Details

Address:
1111 Boul. Dr.-frederik-philips, Ste 420
Montreal, A8 H4M 2X6
Quebec, Canada
Phone (514) 336-0444
Website milestonepharma.com

Stock Details

Ticker Symbol MIST
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001408443
CUSIP Number 59935V107
ISIN Number CA59935V1076
SIC Code 2834

Key Executives

Name Position
Joseph G. Oliveto M.B.A. Chief Executive Officer, President and Director
Amit Hasija Chief Financial Officer and Executive Vice President of Corporate Development
Dr. David B. Bharucha FACC, M.D., Ph.D. Chief Medical Officer
Dr. Philippe Douville M.B.A., Ph.D. Founder, Strategic Advisor and Member of Scientific Advisory Board
Jeff Nelson Chief Operating Officer
Kim Fox Vice President of Communications
Dr. Philip T. Sager FACC, FAHA, FHRS, M.D. Chief Medical Advisor and Member of the Scientific Advisory Board
Dr. Guy Rousseau SVice President of Regulatory Affairs and Quality Management
Anita Holz Vice President and Head of Medical Affairs

Latest SEC Filings

Date Type Title
Mar 28, 2024 8-K Current Report
Mar 21, 2024 8-K Current Report
Mar 21, 2024 10-K Annual Report
Mar 4, 2024 8-K Current Report
Mar 1, 2024 424B5 Filing
Feb 28, 2024 424B5 Filing
Feb 26, 2024 8-K Current Report
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 9, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals